RecruitingPhase 1NCT07150026

An Exploratory Evaluation of the Safety and Efficacy of Vorinostat in Pitt Hopkins Syndrome

Studying Pitt-Hopkins syndrome

Last synced from ClinicalTrials.gov May 17, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Unravel Biosciences, Inc.
Principal Investigator: Neal I Muni, M.D., MSPH
Unravel Biosciences, Inc.
Intervention: Vorinostat (SAHA)(drug)
Enrollment: 5 enrolled
Eligibility: 3-21 years · All sexes
Timeline: 2025 – 2026

Study locations (1)

Grupo de Investigación Clínica PECET (GIC-PECET), Medellín, Colombia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07150026 on ClinicalTrials.gov

Other trials for Pitt-Hopkins syndrome

Additional recruiting or active studies for the same condition.

RECRUITINGPHASE1, PHASE2NCT07135050
Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
Mahzi Therapeutics

See all trials for Pitt-Hopkins syndrome →

← Back to all trials